参麦开肺散对系统性硬化症肺纤维化患者血清IL―6TNF―αTGF―β1水平影响.docVIP

参麦开肺散对系统性硬化症肺纤维化患者血清IL―6TNF―αTGF―β1水平影响 　　【摘 要】目的：观察参麦开肺散治疗系统性硬化症肺纤维化的临床疗效和对血清细胞因子白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、转化生长因子-β1（TGF-β1）的影响。方法：将60例系统性硬化症肺纤维化患者随机分为治疗组和对照组，每组30例。2组均给予醋酸泼尼松片、青霉胺片、维生素E软胶囊等基础治疗，治疗组在基础治疗的基础上给予参麦开肺散，对照组在基础治疗的基础上给予罗红霉素、乙酰半胱氨酸泡腾片。2组均以12周为1个疗程。观察2组临床疗效及治疗前后IL-6、TNF-α、TGF-β1指标变化情况。结果：治疗组显效19例，有效9例，无效2例，总有效率为93.30%；对照组显效13例，有效8例，无效9例，总有效率为70.00%。2组比较，差异有统计学意义（P 0.01）。治疗后，2组IL-6、TNF-α、TGF-β1指标均较治疗前降低（P 0.01），且治疗组优于对照组（P 0.01）。结论：参麦开肺散组方严谨科学，具有较好的临床疗效，安全可靠。 　　【关键词】 系统性硬化症；参麦开肺散；肺纤维化；白细胞介素-6；肿瘤坏死因子-α；转化生长因子-β1 　　【ABSTRACT】Objective：To observe the clinical curative effect of Shenmai Kaifei San（参麦开肺散） 　　in the treatment of systemic sclerosis complicated by pulmonary fibrosis and its effect on the level of IL-6， 　　TNF-α and TGF-β1.Methods：Sixty cases of systemic sclerosis were randomly divided into a treatment group and a control group，30 cases in each.Both groups were given the initial treatment with prednisone acetate tablets，penicillamine tablets and vitamin E soft capsule，based on which the treatment group was given Shenmai Kaifei San and the control group was further treated with roxithromycin and acetylcysteine effervescent tablets.The 2 groups were treated for a course of 12 weeks.The clinical efficacy and the index changes of IL-6，TNF-α and TGF-β1 were observed before and after treatment in the 2 groups.Results：In the treatment group，19 cases were markedly effective，9 cases were effective，2 cases were ineffective，and the total effective rate was 93.30%；while in the control group，13 cases were markedly effective，8 cases were effective，9 cases were invalid，and the total effective rate was 70.00%.The difference was statistically significant between the two groups（P 0.01）.After treatment，the indexes of IL-6，TNF-α and TGF-β1 in the 2 groups were lower than before treatment （P 0.01），and the treatment group was better than the control group（P 0.01）.Conclusion：The prescription of Shenmai Kaifei San is rigorous，scientific，clinically effective，sa